Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.82 USD | -1.26% |
|
+7.18% | -15.42% |
03:15pm | InMode Says FDA Clears Morpheus8 Technology for Soft Tissue Contraction | MT |
Jul. 15 | Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.42% | 1.61B | |
+4.81% | 212B | |
+8.71% | 187B | |
+27.42% | 155B | |
+34.25% | 115B | |
+2.17% | 65.5B | |
+13.83% | 52.87B | |
-3.30% | 45.25B | |
-3.59% | 39.7B | |
+6.61% | 37.72B |
- Stock Market
- Equities
- INMD Stock
- News InMode Ltd.
- Transcript : InMode Ltd., Q3 2023 Earnings Call, Nov 02, 2023